Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 11228380)

1.

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, Goepfert P, Fast P, Berman P, Powell M, Francis D; NIAID AIDS Vaccine Evaluation Group.

Vaccine. 2001 Feb 28;19(15-16):2080-91.

PMID:
11228380
2.

Development of a single-shot subunit vaccine for HIV-1.

Cleland JL, Powell MF, Lim A, Barrón L, Berman PW, Eastman DJ, Nunberg JH, Wrin T, Vennari JC.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S21-6.

PMID:
7865303
3.

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.

Newman MJ, Wu JY, Gardner BH, Anderson CA, Kensil CR, Recchia J, Coughlin RT, Powell MF.

Vaccine. 1997 Jun;15(9):1001-7.

PMID:
9261947
4.

Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.

Powell MF, Eastman DJ, Lim A, Lucas C, Peterson M, Vennari J, Weissburg RP, Wrin T, Kensil CR, Newman MJ, et al.

AIDS Res Hum Retroviruses. 1995 Feb;11(2):203-9.

PMID:
7742035
5.

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W.

Vaccine. 2001 Apr 30;19(23-24):3033-42.

PMID:
11311997
6.

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

Boyle J, Eastman D, Millar C, Camuglia S, Cox J, Pearse M, Good J, Drane D.

Vaccine. 2007 Mar 30;25(14):2541-4. Epub 2006 Dec 29.

PMID:
17240491
7.

Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .

Powell MF, Cleland JL, Eastman DJ, Lim A, Murthy K, Newman MJ, Nunberg JH, Weissburg RP, Vennari JC, Wrin T, et al.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S105-8. Erratum in: AIDS Res Hum Retroviruses 1995 May;11(5):661.

PMID:
7865282
8.

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

O'Hagan DT, Ugozzoli M, Barackman J, Singh M, Kazzaz J, Higgins K, Vancott TC, Ott G.

Vaccine. 2000 Mar 6;18(17):1793-801.

PMID:
10699327
9.

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.

AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32.

PMID:
10029244
10.

Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi.

Ma J, Bulger PA, Davis DR, Perilli-Palmer B, Bedore DA, Kensil CR, Young EM, Hung CH, Seals JR, Pavia CS, et al.

Vaccine. 1994 Aug;12(10):925-32.

PMID:
7975834
11.

Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.

Jankovic D, Caspar P, Zweig M, Garcia-Moll M, Showalter SD, Vogel FR, Sher A.

J Immunol. 1997 Sep 1;159(5):2409-17.

PMID:
9278332
12.

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T; NIAID HIV Vaccine Trials Network.

Vaccine. 2007 Jan 5;25(3):510-8. Epub 2006 Aug 10.

PMID:
17049679
13.

Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.

Wu JY, Gardner BH, Murphy CI, Seals JR, Kensil CR, Recchia J, Beltz GA, Newman GW, Newman MJ.

J Immunol. 1992 Mar 1;148(5):1519-25.

PMID:
1538134
14.

Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates.

Newman MJ, Wu JY, Coughlin RT, Murphy CI, Seals JR, Wyand MS, Kensil CR.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1413-8.

PMID:
1466970
15.
16.

Recombinant HIV-1 glycoprotein 120 induces distinct types of delayed hypersensitivity in persons with or without pre-existing immunologic memory.

Hladik F, Bender S, Akridge RE, Hu YX, Galloway C, Francis D, McElrath MJ.

J Immunol. 2001 Mar 1;166(5):3580-8.

17.

Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.

Cleland JL, Barrón L, Daugherty A, Eastman D, Kensil C, Lim A, Weissburg RP, Wrin T, Vennari J, Powell MF.

J Pharm Sci. 1996 Dec;85(12):1350-7.

PMID:
8961152
18.

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P; AIDS Vaccine Evaluation Group.

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254-61.

PMID:
11873074
19.

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

McCormack S, Tilzey A, Carmichael A, Gotch F, Kepple J, Newberry A, Jones G, Lister S, Beddows S, Cheingsong R, Rees A, Babiker A, Banatvala J, Bruck C, Darbyshire J, Tyrrell D, Van Hoecke C, Weber J.

Vaccine. 2000 Jan 18;18(13):1166-77.

PMID:
10649617
20.

Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.

Cleland JL, Lim A, Daugherty A, Barron L, Desjardin N, Duenas ET, Eastman DJ, Vennari JC, Wrin T, Berman P, Murthy KK, Powell MF.

J Pharm Sci. 1998 Dec;87(12):1489-95.

PMID:
10189254
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk